Agent for treating leishmania infections

US7795406B2 · kind B2 · utility

Assignee

• Mologen AG · DE

Inventors

• Burghardt Wittig · Berlin, DE
• Laura Fuertes-López · Madrid, ES
• Marcos Timon-Jimenez · San Lorenzo de El Escorial, ES

Key dates

• Filing date: Nov 30, 2005
• Grant date: Sep 14, 2010
• Expiry date: Nov 30, 2025

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading “Abstract of the Disclosure.” The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.